Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3a trial of investigational intramuscular MMRV vaccine versus ProQuad as second dose in healthy children
2025-523274-17-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, single-blind trial of GSKVX000000025896 and varicella virus vaccine in measles, mumps, rubella and 1 more (2 arms), sponsored by GSK. Primary endpoints: Measles IgG seroresponse at Day 43, Mumps IgG seroresponse at Day 43 and 6 more. Planned start Sep 2026; status: authorised.
02
Drugs
GSKVX000000025896varicella virus vaccine
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2025-523274-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523274-17-00.